StocksMediumUpdated•Originally published 25 September 2026•Updated 25 September 2026•
1 min read
Jaguar Health Stock Jumps 32% on Rare-Disease Pipeline Updates
Key Facts
1Jaguar Health announced debt-for-equity exchanges that reduced its debt by over $6.7 million.
2The transaction included the retirement of a promissory note as part of the company's balance sheet improvement strategy.
Jaguar Health stock surged 32% to $9.32 driven by updates regarding the company's rare-disease drug pipeline. Media reports indicated that the price action was further amplified by a thin post-split share float following a recent reverse stock split.
This price momentum follows a session where JAGX closed at $7.06 on September 24, 2026, and coincides with ongoing efforts to restructure the balance sheet. The company previously confirmed a debt reduction of over $6.7 million through debt-for-equity exchange agreements involving the retirement of a promissory note.